首页 | 本学科首页   官方微博 | 高级检索  
检索        

异基因造血干细胞移植治疗慢性粒单核细胞白血病及幼年型粒单核细胞白血病
引用本文:邵群,;王志东,;郑晓丽,;董磊,;韩冬梅,;闫洪敏,;王恒湘,;段连宁.异基因造血干细胞移植治疗慢性粒单核细胞白血病及幼年型粒单核细胞白血病[J].中国实验血液学杂志,2014(4):1058-1062.
作者姓名:邵群  ;王志东  ;郑晓丽  ;董磊  ;韩冬梅  ;闫洪敏  ;王恒湘  ;段连宁
作者单位:[1]安徽医科大学北京空军临床学院,北京100142; [2]中国人民解放军空军总医院血液科,北京100142
摘    要:本研究探讨异基因造血干细胞移植治疗慢性粒单核细胞白血病(CMML)及幼年粒单核细胞型白血病(JMML)的疗效及其影响因素.对3例CMML及2例JMML患者接受异基因造血干细胞移植治疗的临床资料进行多参数分析.结果表明,造血干细胞在5例患者中均成功植入,除1例JMML死于移植后并发症外,余4例至今无病生存.移植前疾病负荷、染色体核型及Ⅱ-Ⅳ度aGVHD的发生均对CMML的复发率或无病生存率有相关的影响;低剂量预处理方案优于清髓性预处理方案,而HLA的相合度及干细胞的来源均不影响总的生存率及无复发生存率,在JMML患者中脐带血造血干细胞移植的移植失败率明显高于骨髓或外周血造血干细胞移植;移植前脾脏的大小及是否行脾切除或者脾区照射对移植结果无影响,而移植年龄、GVHD的发生及HbF的水平对移植复发率均有重要意义.结论:异基因骨髓造血干细胞是治疗CMML及JMML的有效方法,但仍存在一系列问题需要解决.

关 键 词:慢性粒单核细胞白血病  幼年粒单核细胞白血病  异基因造血干细胞移植

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia
Institution:SHAO Qun , WANG Zhi-Dong ,ZHENG Xiao-Li, DONG Lei, HAN Dong-Mei , YAN Hong-Ming , WANG Heng-Xiang, DUAN Lian-Ning(1 Department of Hematology, Clinical College of Chinese Air Force, Anhui Medical University, Beijing 100142 ; 2 Department of Hema- tology, Chinese Air Force General Hospital, Beijing 100142, China)
Abstract:This study was purposed to explore the therapentic efficacy and influencing factors of allogeneic hematopoietic stem cell transplantation(allo-HSCT) in patients with chronic myelomonocytic leukemia(CMML) and in patients with juvenile myelomonocytic leukemia (JMML). The clinical data of 3 cases of CMML and 2 cases of JMML underwent allo-HSCT were analysed in term of multiparameter. The results showed that the hematopoictic stem cells in 5 patients grafted successfuly. One case of JMML died of pulmenary disease, other 4 cases survive without disease. The analysis found that the disease burden before transplant, chromosome karyotype, acute GVHD II - IV and poor risk cytogenetics all associated with the relapse rate and disease-free survival rate of CMML. The low intensity conditioning ragimen was better than myeloablative conditioning regimen. Type of donor and source of stem cells did not statistically and significantly affect OS and RFS. The splenectomy before allo-HSCT as well as spleen size at time of the alloHSCT did not influence on posttransplantation outcome of JMML. However, cord blood HSCT for JMML patients delayed hematologic recovery as compared to that of bone marrow or peripheral blood HSCT. The age, GVHD, HbF level played an important rale in leukemia resplase. It is concluded that the allogeneic hematopoietic stem cell transplantation is a curative regimen for CMML and JMML, but there also is a serial problems to be resolved.
Keywords:chronic myelomonocytic leukemia  juvenile myelomonocytic leukemia  hematopoietic stem cell transplantation
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号